Advances in Intrathecal Nanoparticle Delivery: Targeting the Blood-Cerebrospinal Fluid Barrier for Enhanced CNS Drug Delivery

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Aug 29

PMID 39204177

Authors

Ahmad Khalid Madadi

Moon-Jun Sohn

Affiliations

Soon will be listed here.

Abstract

The blood-cerebrospinal fluid barrier (BCSFB) tightly regulates molecular exchanges between the bloodstream and cerebrospinal fluid (CSF), creating challenges for effective central nervous system (CNS) drug delivery. This review assesses intrathecal (IT) nanoparticle (NP) delivery systems that aim to enhance drug delivery by circumventing the BCSFB, complementing approaches that target the blood-brain barrier (BBB). Active pharmaceutical ingredients (APIs) face hurdles like restricted CNS distribution and rapid clearance, which diminish the efficacy of IT therapies. NPs can be engineered to extend drug circulation times, improve CNS penetration, and facilitate sustained release. This review discusses key pharmacokinetic (PK) parameters essential for the effectiveness of these systems. NPs can quickly traverse the subarachnoid space and remain within the leptomeninges for extended periods, often exceeding three weeks. Some designs enable deeper brain parenchyma penetration. Approximately 80% of NPs in the CSF are cleared through the perivascular glymphatic pathway, with microglia-mediated transport significantly contributing to their paravascular clearance. This review synthesizes recent progress in IT-NP delivery across the BCSFB, highlighting critical findings, ongoing challenges, and the therapeutic potential of surface modifications and targeted delivery strategies.

Citing Articles

Nanoparticle Strategies for Treating CNS Disorders: A Comprehensive Review of Drug Delivery and Theranostic Applications.

Toader C, Dumitru A, Eva L, Serban M, Covache-Busuioc R, Ciurea A Int J Mol Sci. 2025; 25(24.

PMID: 39769066 PMC: 11676454. DOI: 10.3390/ijms252413302.

Cerebral Aneurysm: Filling the Gap Between Pathophysiology and Nanocarriers.

Toader C, Radoi M, Covlea C, Covache-Busuioc R, Ilie M, Glavan L Int J Mol Sci. 2024; 25(22).

PMID: 39595942 PMC: 11593836. DOI: 10.3390/ijms252211874.

Murine model of minimally invasive nasal depot (MIND) technique for central nervous system delivery of blood-brain barrier-impermeant therapeutics.

Chua A, Di Francesco V, DSouza A, Amiji M, Bleier B Lab Anim (NY). 2024; 53(12):363-375.

PMID: 39548349 DOI: 10.1038/s41684-024-01460-w.

References

Shi N, Zhang Y, Zhu C, Boado R, Pardridge W . Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci U S A. 2001; 98(22):12754-9. PMC: 60126. DOI: 10.1073/pnas.221450098. View

Wong H, Wu X, Bendayan R . Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev. 2011; 64(7):686-700. DOI: 10.1016/j.addr.2011.10.007. View

Umezawa F, Eto Y . Liposome targeting to mouse brain: mannose as a recognition marker. Biochem Biophys Res Commun. 1988; 153(3):1038-44. DOI: 10.1016/s0006-291x(88)81333-0. View

Sabatier J, Vives E, Mabrouk K, Benjouad A, Rochat H, Duval A . Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol. 1991; 65(2):961-7. PMC: 239839. DOI: 10.1128/JVI.65.2.961-967.1991. View

Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli M, Forni F . Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Release. 2005; 108(1):84-96. DOI: 10.1016/j.jconrel.2005.07.013. View

Joseph A, Nance E . Nanotherapeutics and the Brain. Annu Rev Chem Biomol Eng. 2022; 13:325-346. PMC: 9236656. DOI: 10.1146/annurev-chembioeng-092220-030853. View

Bode U, Magrath I, Bleyer W, Poplack D, Glaubiger D . Active transport of methotrexate from cerebrospinal fluid in humans. Cancer Res. 1980; 40(7):2184-7. View

Rall D . Transport through the ependymal linings. Prog Brain Res. 1968; 29:159-72. DOI: 10.1016/S0079-6123(08)64154-0. View

Saul J, Annapragada A, Natarajan J, Bellamkonda R . Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release. 2003; 92(1-2):49-67. DOI: 10.1016/s0168-3659(03)00295-5. View

10.

Maarup T, Chen A, Porter F, Farhat N, Ory D, Sidhu R . Intrathecal 2-hydroxypropyl-beta-cyclodextrin in a single patient with Niemann-Pick C1. Mol Genet Metab. 2015; 116(1-2):75-9. PMC: 4633280. DOI: 10.1016/j.ymgme.2015.07.001. View

11.

BERG , Poplack . Treatment of Meningeal Malignancy. Oncologist. 1996; 1(1 & 2):56-61. View

12.

Glantz M, Lafollette S, Jaeckle K, Shapiro W, Swinnen L, Rozental J . Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999; 17(10):3110-6. DOI: 10.1200/JCO.1999.17.10.3110. View

13.

Mendez-Gomez H, Galera-Prat A, Meyers C, Chen W, Singh J, Carrion-Vazquez M . Transcytosis in the blood-cerebrospinal fluid barrier of the mouse brain with an engineered receptor/ligand system. Mol Ther Methods Clin Dev. 2015; 2:15037. PMC: 4596253. DOI: 10.1038/mtm.2015.37. View

14.

Megias-Vericat J, Garcia-Robles A, Company-Albir M, Fernandez-Megia M, Perez-Miralles F, Lopez-Briz E . Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases. Neurol Sci. 2017; 38(5):727-743. DOI: 10.1007/s10072-017-2833-9. View

15.

Jiang X, Xin H, Ren Q, Gu J, Zhu L, Du F . Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials. 2013; 35(1):518-29. DOI: 10.1016/j.biomaterials.2013.09.094. View

16.

van Deurs B, Moller M, Amtorp O . Uptake of horseradish peroxidase from CSF into the choroid plexus of the rat, with special reference to transepithelial transport. Cell Tissue Res. 1978; 187(2):215-34. DOI: 10.1007/BF00224366. View

17.

Weitman S, Frazier K, Kamen B . The folate receptor in central nervous system malignancies of childhood. J Neurooncol. 1994; 21(2):107-12. DOI: 10.1007/BF01052894. View

18.

Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P . Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014; 81(1):49-60. DOI: 10.1016/j.neuron.2013.10.061. View

19.

Dai H, Navath R, Balakrishnan B, Guru B, Mishra M, Romero R . Intrinsic targeting of inflammatory cells in the brain by polyamidoamine dendrimers upon subarachnoid administration. Nanomedicine (Lond). 2010; 5(9):1317-29. PMC: 3095441. DOI: 10.2217/nnm.10.89. View

20.

Tumani H, Huss A, Bachhuber F . The cerebrospinal fluid and barriers - anatomic and physiologic considerations. Handb Clin Neurol. 2017; 146:21-32. DOI: 10.1016/B978-0-12-804279-3.00002-2. View